BLSM (46) FTH (39) EOLS (21) CTMX (20) ⌘ Pro Terminal →

Monopar Therapeutics Inc. (MNPR) — RQD Stock Rating Cockpit

$71.91 -2.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Monopar Therapeutics Inc. (MNPR) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $482.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MNPR)Realized 20D OHLCV Swing Band: ±11.4%

RSI-14 MOMENTUMNEUTRAL RANGE

33.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE29% OF RANGE

L: $50$71.91H: $125

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 9 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on MNPR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-17.4% ROIC with 42.0% gross margin and -2.53% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (28)

9/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like MNPR

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MNPR)

✓Walkthrough of MNPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MNPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.89%🛡️ HOLDING TREND SUPPORT

2026-10-30O $71.36H $72.76L $69.30C $71.91VOL 197.8K

RES: $126.7SUP: $70.02SMA50: $91.08SMA200: $77.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MNPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MNPR Butterfly Map → + Track MNPR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MNPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MNPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MNPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNPR)

Health Care Rank #916 of 1016 ⚔️ BLSM vs MNPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MNPR vs. BLSM, FTH, EOLS, CTMX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Monopar Therapeutics Inc. (MNPR) ranks #916 by composite RQD confidence (31/100, grade E) and #460 by equity capitalization ($482.7M). Within this direct 5-issuer industry benchmark cohort, MNPR leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. BLSM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MNPR at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MNPR ACTIVE Monopar Therapeutics Inc.	E	31/100	—	—	-17.4%	-2.02%	$482.7M	Benchmark Subject
BLSM BlossomHill Therapeutics Inc.	D	46/100	—	—	—	-7.59%	$483.4M	/blsm-vs-mnpr →
FTH Faeth Therapeutics Inc.	D-	39/100	—	—	-35.0%	-2.34%	$484.5M	/fth-vs-mnpr →
EOLS Evolus Inc.	E	21/100	—	66.3%	-35.0%	-1.51%	$496.7M	/eols-vs-mnpr →
CTMX CytomX Therapeutics Inc.	E	20/100	—	—	-20.5%	-2.97%	$499.0M	/ctmx-vs-mnpr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001645469

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Monopar Therapeutics Inc. (MNPR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.7M, operating cash flow of -$12.2M, and free cash flow of -$12.2M (-90.5% YoY). On the balance sheet, MNPR closed FY2025 with $140.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$13.7M	-$12.2M	-$12.2M	$140.7M	—
FY2024 (FY)	2024-12-31	$0	-$15.6M	-$6.4M	-$6.4M	$60.3M	—
FY2023 (FY)	2023-12-31	$0	-$8.4M	-$7.9M	-$7.9M	—	—

3. MNPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MNPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Monopar Therapeutics Inc. (NASDAQ: MNPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $71.91 (-2.02% 1D, market cap $482.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MNPR ranks #916 in composite RQD confidence.

How does MNPR compare to BLSM and FTH in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNPR carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -17.4%. By comparison, BLSM (BlossomHill Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $483.4M) and FTH (Faeth Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $484.5M). Among the 5-stock peer group, MNPR leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MNPR?

Per MNPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645469), Monopar Therapeutics Inc. generated $0 in revenue, -$13.7M in net income, and -$12.2M in free cash flow against $140.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MNPR trading relative to its 50-day, 200-day, and 52-week technical levels?

MNPR last traded at $71.91 (-2.02% on volume of 163,116 shares), positioning the stock -21.05% below its 50-day simple moving average ($91.08) and -6.90% below its 200-day simple moving average ($77.24). Across its 52-week range of $50.07 to $124.82, MNPR sits at the 29.2% percentile with a 14-day RSI of 33.4 (NEUTRAL RANGE) and an implied next-earnings move of ±11.4% ($63.71 to $80.11).

MNPR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MNPR stock right now?

Monopar Therapeutics Inc. (MNPR) currently earns a Roarable Rating of E (Strong Sell — SELL) with 31/100 RQD Confidence. Stretched risk/reward at current multiples (-17% return on capital) under elevated 10-year interest-rate pressure.

What is MNPR's 12-month price target and RQD AI Jury consensus?

MNPR's 12-month base price target is $63.17 (range $49.27 to $131.06), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MNPR RQD Cockpit MNPR 12M Forecast MNPR Earnings & Move MNPR Dividends & DRIP MNPR Insiders & 13F MNPR Whale Options MNPR Profit Sankey MNPR News & Why